Referred to the House Committee on Energy and Commerce.

Original title: “HR 10708: To authorize the Secretary of Health and Human Services to award grants to reduce barriers to immigrants becoming nurses or allied health professionals in the United States, and for other purposes.”

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Original title: “HR 10716: To amend title XI of the Social Security Act to clarify the authority of the Inspector General of the Department of Health and Human Services to exclude certain entities from participation in Federal health care programs.”

In accordance with the National Institutes of Health (NIH), Tribal Consultation Policy, the NIH will hold two Tribal Consultations and one Tribal listening session at the National Congress of American Indians (NCAI) Annual Convention. The first consultation will discuss two new proposed initiatives of the NIH All of Us Research Program. The second consultation will discuss the National Institute of Minority Health and Health Disparities (NIMHD) proposed renewal initiative for the Resource Center

Original title: “Notice of NIH Tribal Consultations and Listening Session”

The Agency for Toxic Substances and Disease Registry (ATSDR), within the Department of Health and Human Services (HHS), announces the opening of a docket to obtain comments on a draft of the updated Toxicological Profiles for Cadmium and Hexachlorocyclopentadiene. This action provides an opportunity for the public and organizations to submit comments on drafts of the profiles. In particular, ATSDR is interested in any relevant additional information, data, research studies, or reports on the hea

Original title: “Availability of Two Draft Toxicological Profiles”

The Food and Drug Administration (FDA) is announcing the renewal of the Dermatologic and Ophthalmic Drugs Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Dermatologic and Ophthalmic Drugs Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the October 7, 2028, expiration date.

Original title: “Advisory Committee; Dermatologic and Ophthalmic Drugs Advisory Committee; Renewal”

The Food and Drug Administration (FDA) is announcing the renewal of the Antimicrobial Drugs Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Antimicrobial Drugs Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the October 7, 2028, expiration date.

Original title: “Advisory Committee; Antimicrobial Drugs Advisory Committee; Renewal”

The Food and Drug Administration (FDA or Agency) is requesting that any consumer organizations interested in participating in the selection of voting and/or nonvoting consumer representatives to serve on its advisory committees or panels notify FDA in writing. FDA is also requesting nominations for voting and/or nonvoting consumer representatives to serve on advisory committees and/or panels for which vacancies currently exist or are expected to occur in the near future. Nominees recommended to

Original title: “Request for Nominations for Individuals and Consumer Organizations for Advisory Committees”

The Food and Drug Administration (FDA or Agency) is requesting nominations for qualified individuals to serve as voting members of FDA's standing public advisory committees and panels (collectively, advisory committees). This notice covers scientific, technical, professional, and other voting-member positions in which appointees serve as individuals rather than as designated representatives; it does not solicit nominations for consumer representative or industry representative positions. FDA wil

Original title: “Request for Nominations for Voting Members of Food and Drug Administration Advisory Committees”

HHS, through ARPA-H, launched a major effort to transform how clinical trials are designed and conducted through new SURPASS program. Beyond individual trials, these efforts are intended to create broadly useful tools, frameworks, and examples for the U.S. clinical trial ecosystem. Publicly available regulatory documents, validated standards, and real-world demonstrations of modernized trial methods could help sponsors, sites, regulators, and technology developers adopt more adaptive and efficient approaches across many diseases. The new Simulation-augmented, Real-time Platform Adaptive Seamless Trials (SURPASS) program, together with three complementary projects announced today, aims to remove barriers that slow clinical development and help promising treatments reach patients sooner. Together, these efforts advance the Trump administration's work to modernize clinical development, reduce unnecessary delays and costs, and strengthen U.S. competitiveness in biotechnology and drug development. By making clinical trials faster, more efficient, and less burdensome for patients, ARPA-H aims to help promising treatments reach patients sooner while reinforcing the United States as a global leader in medical innovation. Create an agentic operations layer to reduce time and cost by automating key trial startup and operational activities, supporting onboarding of new treatment arms, and speeding data collection, cleaning, and dataset construction. To support this broader transformation of the U.S. clinical trial ecosystem, ARPA-H is also announcing three complementary projects that address critical infrastructure challenges beyond trial design itself:

Original title: “HHS Launches SURPASS and New Efforts to Accelerate Faster, Smarter Clinical Trials | HHS.gov”

The U.S. Food and Drug Administration today announced a broad, nationwide recruitment effort to expand the range of qualified voices and perspectives on its advisory committees— the independent bodies that inform some of the most consequential decisions in American public health.

Original title: “FDA Launches Nationwide Effort to Expand Scientific Expertise and Consumer Voices to Advisory Committees”

By the end of 2026, EMA will develop a regulatory roadmap to help drive decisive change on how women’s health is considered across medicines development and regulation. This…, Women are still missing: from research and data, prevention, diagnosis and treatment. But the momentum to improve support for women’s health has never been stronger.…, Meaningful change starts with dialogue and with a shared understanding of the challenges we face. We end this workshop with a clear path to

Original title: “Women are missing from medicines development: EMA’s roadmap for change”

The Food and Drug Administration (FDA, Agency, or we) has determined that ISTURISA (osilodrostat) tablets, 10 milligrams (mg), was not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for osilodrostat tablets, 10 mg if all other legal and regulatory requirements are met.

Original title: “Determination That ISTURISA (Osilodrostat) Tablets, 10 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness”

The Food and Drug Administration (FDA) is classifying the flushing and storage solution for vascular autografts at room temperature into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the flushing and storage solution for vascular autografts at room temperature. We are taking this action because we have determined that classifying the device into class II will provide a r

Original title: “Medical Devices; Gastroenterology-Urology Devices; Classification of the Flushing and Storage Solution for Vascular Autografts at Room Temperature”

Read twice and referred to the Committee on Finance.

Original title: “S 5672: Patients First Act of 2026”

This document corrects technical errors in the final rule that appeared in the August 3, 2026 Federal Register titled "Medicare Program; FY 2027 Hospice Wage Index and Payment Rate Update and Hospice Quality Reporting Program Requirements".

Original title: “Medicare Program; FY 2027 Hospice Wage Index and Payment Rate Update and Hospice Quality Reporting Program Requirements; Correction”

This document corrects technical errors in the final rule that appeared in the July 31, 2026 Federal Register titled "Medicare Program; Prospective Payment System and Consolidated Billing for Skilled Nursing Facilities; Updates to the Quality Reporting Program for Federal Fiscal Year 2027."

Original title: “Medicare Program; Prospective Payment System and Consolidated Billing for Skilled Nursing Facilities; Updates to the Quality Reporting Program for Federal Fiscal Year 2027; Correction”

In accordance with the Federal Advisory Committee Act (FACA), the Department of Health and Human Services is hereby giving notice that the Council on Graduate Medical Education (COGME or Council) has been recharted. The effective date of the charter renewal is September 30, 2026.

Original title: “Recharter for the Council on Graduate Medical Education”